Coronavirus Research
Overview
Overview
The J. Craig Venter Institute (JCVI) has been involved in viral sequencing and analysis for more than 25 years, and coronavirus research for more than 15. This work has aided human health through vaccine development; improved food security by protecting crops and livestock; and provides critical data and analysis to researchers around the world. The Institute has also pioneered a synthetic biology platform which is now integral to fighting current and emerging viral threats.
Following is a summary of our various research projects on the novel coronavirus, SARS-CoV-2.
SARS-CoV-2 Research
COVID-19 Serology Testing
Informatics
JCVI is developing critical resources for the evaluation of antibody reactivity for serology testing. From an informatics perspective, the use of comparative genomics methods and predictive machine learning algorithms are being used to identify the key determinants for immune system recognition and to monitor the impact of virus evolution in immune system evasion. The bioinformatics analyses will aid in developing critical resources for the evaluation of antibody reactivity for serology testing.
Lab
In the laboratory, viral surface proteins are being generated for use as ELISA antigens, pseudotyped recombinant viruses are being constructed for neutralizing assays, and candidate vaccine constructs are being synthetized to define the immunogenicity of the viral proteins and to understand the basis of immune response and protection against SARS-CoV-2.
Funding
Funding for this research is provided through a variety of government and private sources.
We need your support now to continue and to expand upon these critical projects. If you would like to learn more about supporting any of this exciting research, please contact Jill Mullen at jmullen@jcvi.org.
your support nowRelated Information
Coronavirus Support
Your support directly funds novel coronavirus research. This is monumental effort, requiring a wide range of scientific solutions. We need your support.
Donate NowPrincipal Investigators
- Marcelo Freire, DDS, PhD, DMedSc
- John Glass, PhD
- Richard H. Scheuermann, PhD
- Gene S. Tan, PhD
- Sanjay Vashee, PhD
Related Research
Publications
Publications
The Lancet. Infectious diseases. 2025-05-01; 25.5: e294-e306.
Targeting the SARS-CoV-2 reservoir in long COVID
Scientific reports. 2024-11-12; 14.1: 27637.
Major alteration of lung microbiome and the host responses in critically ill COVID-19 patients with high viral load
Expert review of respiratory medicine. 2024-10-01; 18.10: 815-829.
The unique metabolic and lipid profiles of patients with severe COVID-19 compared to severe community-acquired pneumonia: a potential prognostic and therapeutic target
PloS one. 2024-07-25; 19.7: e0300408.
Sputum production and salivary microbiome in COVID-19 patients reveals oral-lung axis
PLoS pathogens. 2024-05-23; 20.5: e1011669.
SARS-CoV-2 ORF8 modulates lung inflammation and clinical disease progression
Nature immunology. 2023-10-01; 24.10: 1778.
Author Correction: SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)
Nature immunology. 2023-10-01; 24.10: 1616-1627.
SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)
mBio. 2023-08-31; 14.4: e0119423.
SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection
Heliyon. 2023-07-04; 9.7: e17958.
Persistent immune and clotting dysfunction detected in saliva and blood plasma after COVID-19
Cell reports. Medicine. 2023-06-20; 4.6: 101088.
Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
Nature communications. 2023-05-25; 14.1: 3026.
A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8
Emerging infectious diseases. 2023-05-01; 29.5:
US National Institutes of Health Prioritization of SARS-CoV-2 Variants
Critical care (London, England). 2023-04-20; 27.1: 155.
Major adverse cardiovascular events are associated with necroptosis during severe COVID-19
STAR protocols. 2022-12-16; 3.4: 101835.
A high-throughput SARS-CoV-2 pseudovirus multiplex neutralization assay
Frontiers in bioinformatics. 2022-10-24; 2.1020189.
Early detection of emerging SARS-CoV-2 variants of interest for experimental evaluation
eLife. 2022-10-14; 11.
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study
Scientific reports. 2022-10-06; 12.1: 16731.
A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron
Proceedings of the National Academy of Sciences of the United States of America. 2022-09-13; 119.37: e2204717119.
SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis
Cell reports. Medicine. 2022-06-21; 3.6: 100640.
TNF-α+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies
Nature. 2022-05-01; 605.7911: 640-652.
Defining the risk of SARS-CoV-2 variants on immune protection
mSystems. 2022-04-26; 7.2: e0146621.
High-Content Screening and Computational Prediction Reveal Viral Genes That Suppress the Innate Immune Response
Science translational medicine. 2022-03-09; 14.635: eabm7853.
Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity
Science translational medicine. 2022-03-02; 14.634: eabn7842.
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
Journal of leukocyte biology. 2021-12-01; 110.6: 1225-1239.
Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation
Journal of virology. 2021-09-27; 95.20: e0101021.
Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19
Cell reports. Medicine. 2021-07-20; 2.7: 100355.
Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals
Advanced drug delivery reviews. 2021-05-01; 172.314-338.
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Nature medicine. 2021-05-01; 27.5: 892-903.
SARS-CoV-2 infection of the oral cavity and saliva
Viruses. 2021-04-01; 13.4:
Rescue of Infectious Sindbis Virus by Yeast Spheroplast-Mammalian Cell Fusion
bioRxiv : the preprint server for biology. 2021-03-01;
Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees
Nature immunology. 2021-01-01; 22.1: 67-73.
Proinflammatory IgG Fc structures in patients with severe COVID-19
Scientific data. 2020-06-19; 7.1: 188.
COVID-19 pandemic reveals the peril of ignoring metadata standards
Proceedings of the National Academy of Sciences of the United States of America. 2020-06-09; 117.23: 12522-12523.
Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable
Cell host & microbe. 2020-04-08; 27.4: 671-680.e2.
A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2
Scientific data. 2014-10-14; 1.140033.
A comprehensive collection of systems biology data characterizing the host response to viral infection
The Journal of general virology. 2014-04-01; 95.Pt 4: 836-848.
Isolation, propagation, genome analysis and epidemiology of HKU1 betacoronaviruses
Viruses. 2012-11-19; 4.11: 3209-26.
Virus pathogen database and analysis resource (ViPR): a comprehensive bioinformatics database and analysis resource for the coronavirus research community
The Journal of general virology. 2012-11-01; 93.Pt 11: 2387-2398.
Genomic analysis of 16 Colorado human NL63 coronaviruses identifies a new genotype, high sequence diversity in the N-terminal domain of the spike gene and evidence of recombination
Virology. 2012-09-01; 430.2: 90-9.
Characterization of a recombinant canine coronavirus with a distinct receptor-binding (S1) domain
Emerging infectious diseases. 2012-07-01; 18.7: 1089-95.
Spike protein fusion peptide and feline coronavirus virulence
Nucleic acids research. 2012-07-01; 40.Web Server issue: W186-92.
VIGOR extended to annotate genomes for additional 12 different viruses
The Journal of general virology. 2011-06-01; 92.Pt 6: 1369-79.
Molecular characterization of a new species in the genus Alphacoronavirus associated with mink epizootic catarrhal gastroenteritis
PLoS pathogens. 2010-05-06; 6.5: e1000896.
Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing
Journal of virology. 2008-12-01; 82.24: 12422-31.
Bovine-like coronaviruses isolated from four species of captive wild ruminants are homologous to bovine coronaviruses, based on complete genomic sequences
Virology. 2007-06-20; 363.1: 1-10.
Quasispecies of bovine enteric and respiratory coronaviruses based on complete genome sequences and genetic changes after tissue culture adaptation
Virology. 2007-02-20; 358.2: 424-35.
Complete genomic sequences, a key residue in the spike protein and deletions in nonstructural protein 3b of US strains of the virulent and attenuated coronaviruses, transmissible gastroenteritis virus and porcine respiratory coronavirus
News
Groundbreaking study reveals oral microbiome’s role in immune response and COVID-19 severity
Newly developed AI model shows that saliva is a better predictor of COVID-19 severity than existing blood tests
New LongCOVID research launched by PolyBio’s global consortium of scientists
Funding will deepen research on the persistence of the SARS-CoV-2 virus in LongCOVID patients and launch new clinical trials
PolyBio Research Foundation Consortium & colleagues publishes Nature position paper on SARS-CoV-2 reservoir in Long COVID/PASC
Family resemblance: How T cells could fight many coronaviruses at once
LJI researchers work to head off future pandemics by uncovering key similarities between SARS-CoV-2 and common cold coronaviruses
Scientists aim to develop vaccine against all deadly coronaviruses
$8 million NIH grant supports effort to avert next pandemic
Top scientists join forces to study leading theory behind long COVID
Several JCVI scientists will be contributing to the newly launched Long Covid Research Initiative — a collaboration of researchers, clinicians, and patients working to rapidly study and treat long Covid.
Omicron and Beta variants evade antibodies elicited by vaccines and previous infections, but boosters help
Pregnancy also contributes to a reduced COVID-19 antibody response
SARS-CoV-2 Mutation Tracking
Influenza A Virus Discovered in Heart Muscle Tissue Causing Damage Long After It Has Cleared from the Lungs
Strategies to inhibit necrotic cell death or to prevent mitochondrial damage should be pursued as possible therapies to reduce cardiac damage during influenza infections
Scientists rush to determine if mutant strain of coronavirus will deepen pandemic
U.S. researchers have been slow to perform the genetic sequencing that will help clarify the situation
Unique Antibody Pattern Discovered in COVID-19 ICU Patients May Be Key to Predicting Severe Outcomes
COVID-19 Further Complicating Flu Season
Study reveals mouth as primary source of COVID-19 infection, spread
UNC-Chapel Hill, NIH identify sites in the oral cavity where coronavirus can take hold
Online Education Resources to Help With Your New “Normal”
Coronavirus Pandemic: Putting Comprehensive Genomic Data in the Hands of Frontline Researchers Worldwide is Paramount
LJI Scientists Identify Potential Targets for Immune Responses to Novel Coronavirus
The research, which includes comparative genomics analysis by JCVI scientists Yun Zhang and Richard Scheuermann, provides essential information about the human immune response to coronavirus infection that will guide the design and evaluation of diagnostics and vaccine candidates